TY  - JOUR
AU  - Teófilo, Eugénio
AU  - Rocha-Pereira, Nuno
AU  - Kuhlmann, Birger
AU  - Antela, Antonio
AU  - Knechten, Heribert
AU  - Santos, Jesús
AU  - Jiménez-Expósito, Maria Jesús
AU  - REMAIN study group
PY  - 2016
DO  - 10.1080/15284336.2015.1112494
SN  - 1528-4336
UR  - http://hdl.handle.net/10668/9851
T2  - HIV clinical trials
AB  - Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited. We...
LA  - en
KW  - HIV-1
KW  - antiretroviral therapy
KW  - estimated glomerular filtration rate
KW  - hyperbilirubinemia
KW  - observational study
KW  - persistence
KW  - resistance
KW  - ritonavir-boosted atazanavir
KW  - Adolescent
KW  - Adult
KW  - Atazanavir Sulfate
KW  - Cohort Studies
KW  - Drug Administration Schedule
KW  - Europe
KW  - Female
KW  - HIV Infections
KW  - HIV-1
KW  - Humans
KW  - Kidney Diseases
KW  - Male
KW  - Middle Aged
KW  - Ritonavir
KW  - Treatment Outcome
KW  - Young Adult
TI  - Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
TY  - research article
VL  - 17
ER  -